美女免费一级视频在线观看

    1. <form id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></form>
      <address id=BiMYPaeIF><nobr id=BiMYPaeIF><nobr id=BiMYPaeIF></nobr></nobr></address>

      Sandoz CEO Richard Saynor discussed navigating tariffs and the “distorted” U.S. drug market. As big drug companies line up to announce new U.S. jobs and plants in the face of Trump tariff threats, generics giant Sandoz is sending a different message. (Axios) 

      Illumina CEO Jacob Thaysen sees a path to stable growth, even as the company’s academic customers face funding uncertainty. Thaysen talks about NIH research cuts and a shift in corporate philosophy. (STAT News)

      Vinay Prasad, who briefly left his role as head of the FDA’s Center for Biologics Evaluation and Research, has come back to the agency without certain responsibilities. Prasad has returned with fewer titles and a seemingly lower profile. (Endpoints News)

      Regeneron said that its immune disorder therapy improves daily function in a clinical trial. The treatment helped improve functions like talking and eating. (Reuters) 

      The Department of Health and Human Services reiterated that it will reveal the cause of autism by September. HHS Secretary Kennedy said they have been tracking the disease, and are on track to identifying the cause of the disease next month. (The Hill)  

      To read yesterday’s edition of Five things for pharma marketers to know, click here.